Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26033166 | 0.90 | POLB (0.59) | LMNACYP2C9POLBMAPTAPEX1 | |
| SCHEMBL1015289 | 0.89 | CYP2C9 (0.56) | LMNACYP2C9 | |
| SCHEMBL13628645 | 0.83 | CYP2C9 (0.54) | LMNACYP2C9 | |
| SCHEMBL2619535 | 0.78 | CYP2C9 (0.51) | LMNACYP2C9 | |
| SCHEMBL12918706 | 0.77 | CYP2C9 (0.53) | LMNACYP2C9 | |
| SCHEMBL26033094 | 0.77 | CYP2C9 (0.55) | LMNACYP2C9 | |
| SCHEMBL13554801 | 0.76 | CYP2C9 (0.51) | LMNACYP2C9 | |
| SCHEMBL4434064 | 0.76 | CYP2C9 (0.54) | LMNACYP2C9GAA | |
| SCHEMBL10238310 | 0.76 | CYP2C9 (0.54) | LMNACYP2C9 | |
| SCHEMBL1014694 | 0.75 | CYP2C9 (0.61) | CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281089-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281089-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | LMNA 3716/4885CYP2C9 4725/4885POLB 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.